Gamma-Aminobutyric Acid

Gamma-aminobutyric acid (GABA) is a four-carbon amino acid whose amino group sits on the gamma carbon, away from the carboxyl group. Unlike the twenty standard amino acids, it is not a building block of proteins. Its importance comes from its role as the principal neurotransmitter that dampens activity in the central nervous system. In adult mammals, GABA-releasing neurons provide most of the inhibition that keeps neural circuits from firing excessively, so the balance between excitation and inhibition depends heavily on it. Disturbances in GABA signaling are linked to conditions such as epilepsy, anxiety disorders, and sleep problems, and many clinically used sedatives and anesthetics act on GABA receptors.

The molecule is also notable for its metabolic position. It is made from glutamate, the main excitatory amino acid, and it is broken down through a short route that feeds into the citric acid cycle, a pathway known as the GABA shunt. This biochemical loop links neurotransmission to central energy metabolism and to the nitrogen balance of cells, and the same pathway operates in plants and many microorganisms. Research on GABA therefore spans neuroscience, pharmacology, biochemistry, and food and agricultural science.

This entry first describes the chemistry of GABA and then follows its life cycle: synthesis, breakdown, storage and release, and receptor action. It then covers its functions in the brain and in other organs and organisms, the diseases that result from defects in its metabolism, and the drugs that target its system. The final sections address industrial production, the history of its discovery, and questions that remain open.

Chemical identity and physical properties

Gamma-aminobutyric acid (GABA) has the systematic IUPAC name 4-aminobutanoic acid and the formula C4H9NO2, giving a molar mass of about 103 g/mol. The molecule is a straight chain of four carbons. Counting from the carboxyl carbon as C1, the amino group sits on C4. Greek-letter naming places the carbon next to the carboxyl at alpha, the next at beta, and the third at gamma, so the amino group is on the gamma carbon, three carbons removed from the carboxyl group. The compound is typically a white crystalline powder. Because the chain has no stereocenter, GABA is achiral, which distinguishes it from most biological amino acids.

GABA is classed as a non-proteinogenic amino acid because it is not incorporated into proteins during translation. The term "amino acid", used without qualification in biochemistry, usually means an alpha-amino acid, in which the amino and carboxyl groups are bonded to the same carbon. The twenty standard protein building blocks all have this arrangement. In GABA, the amino group is separated from the carboxyl group by a chain of methylene units, so the molecule is not an alpha-amino acid. This is why many scientific and medical texts rarely call it an amino acid at all, even though it has the amino and carboxyl functional groups. Other non-proteinogenic compounds such as L-DOPA and carnitine share this status.

In aqueous solution, GABA exists mainly as a zwitterion, in which the carboxyl group is deprotonated (carboxylate, negative) and the amino group is protonated (ammonium, positive). Its two ionizable groups have approximate pKa values near 4 and 10.5, so at physiological pH the molecule carries no net charge while retaining separated positive and negative centers. This dipolar character accounts for its high water solubility. It also explains why GABA crosses lipid membranes poorly by passive diffusion: the charged ends favor water over the hydrocarbon interior of the bilayer. Movement across cell membranes therefore depends largely on dedicated transporter proteins. The same two-ended charge pattern matters for receptor recognition, since ligand-binding pockets for GABA must accommodate both the ammonium and the carboxylate, and the relative spacing of these groups determines how well GABA fits its binding sites.

Glutamate (glutamic acid) is the closest relative of GABA and the main excitatory neurotransmitter in the mammalian brain. It is a five-carbon molecule, 2-aminopentanedioic acid, and it is a true alpha-amino acid that is incorporated into proteins. Its extra carboxyl group sits on the side chain, so glutamate has two carboxylates and one ammonium group. At physiological pH it carries a net negative charge of roughly −1, whereas GABA is neutral. This difference in charge affects how each molecule is handled by transporters, enzymes, and receptors. The relationship between the two is chemically direct: removing the alpha-carboxyl group from glutamate, which releases carbon dioxide, leaves the amino group on the former gamma carbon and produces GABA. This decarboxylation step connects the two molecules in biosynthesis and forms the basis of the metabolic relationships described in later sections.

Biosynthesis and its regulation

GABA is made in a single step from L-glutamate. Glutamate decarboxylase (GAD, EC 4.1.1.15) is a pyridoxal 5′-phosphate (PLP)-dependent enzyme that catalyzes the irreversible α-decarboxylation of L-glutamate to produce γ-Aminobutyric acid (GABA). The enzyme depends on a cofactor derived from the diet: like other amino acid decarboxylases, this enzyme needs Vitamin B6 (pyridoxal phosphate) as a cofactor. Because the same cofactor serves many enzymes of amino acid metabolism, a shortage of vitamin B6 can in principle limit GABA synthesis indirectly.

Mammals express two GAD isoforms, named for their apparent molecular weights of 65 and 67 kDa. Despite 81% sequence similarity, GAD65 (but not GAD67) cycles between an inactive apo-form and an active PLP-bound state; this activity represents a key control mechanism for GABA synthesis. The two forms therefore differ mainly in how they handle their cofactor. GAD67 binds the coenzyme pyridoxal 5-phosphate (PLP) tightly and is constitutively active, producing ~90% of basal GABA levels in the brain. GAD65, by contrast, provides a regulated reserve that can be switched between active and inactive states. Their locations also differ. GAD65 is a synaptic vesicle-associated antigen that catalyzes synthesis of γ-aminobutyric acid (GABA) from l-glutamate. In cell models, GAD67 is instead found in the cytosol, which suggests that membrane association depends on GAD65. Both isoforms occur in the brain and in pancreatic tissue. GAD65 and GAD67 are widely distributed within the central nervous system, pancreas, and other organs. Within the brain, GAD is largely confined to GABA-releasing cells. The rate-limiting enzyme in GABA synthesis, GAD, is found almost exclusively in the inhibitory neurons that release GABA as a neurotransmitter.

Calcium signaling is thought to act on GAD through calmodulin, a Ca²⁺-binding protein. The C-terminal part of GAD65 carries a calmodulin-binding region, and this interaction is necessary for proper regulation of GABA production. This interaction occurs at the C-terminal CaM-binding domain (CaMBD) and is necessary for proper regulation of GABA production. The model usually described is autoinhibitory: the C-terminal region restrains catalysis until Ca²⁺-bound calmodulin engages it. Structural work supports a link between this region and the enzyme's own inactivation. The conformation of the catalytic loop is intimately linked to the C-terminal domain, which also affects the rate of autoinactivation. Molecular dynamics simulations further indicate that coupling between the C-terminal domain, catalytic loop, and pyridoxal 5′-phosphate–binding domain drives structural rearrangement, dimer opening, and autoinactivation.

The decarboxylation step is effectively one-way. The reaction from glutamate to GABA is essentially irreversible. Because the cell cannot reverse this step, the amount of GABA made is governed by how much GAD is active, not by how much glutamate is available. GAD is also the enzyme that sets the pace of production. Glutamate decarboxylase is the major, rate-limiting enzyme in brain for synthesizing gamma-aminobutyric acid (GABA). Its capacity exceeds what is needed: total GAD activity in brain is 10–20 times greater than the observed rate of GABA synthesis, indicating that GAD operates at only a fraction of its capacity. Since the enzyme is usually not working at full capacity, changes in its activation state, rather than its abundance alone, determine how much GABA is produced. Substrate supply is also seldom the constraint: saturation concentrations of L-glutamic acid are present in the presynaptic neuron, so increased substrate concentrations do not normally affect the rate of GABA synthesis.

Catabolism and the GABA shunt

Entry into mitochondria and the transamination step

Most GABA that is not reused for signaling is degraded inside mitochondria, in the mitochondrial matrix. In plants, a GABA permease carries the amino acid into the organelle before breakdown begins. GABA is synthesized from glutamate or arginine and transferred by a GABA permease to mitochondria, where it is catabolized by GABA transaminase and succinate semialdehyde dehydrogenase to succinate.

The first enzymatic step is transamination by GABA transaminase (GABA-T), which takes the amino group from GABA and places it on α-ketoglutarate. The products are glutamate and succinic semialdehyde (SSA). Because α-ketoglutarate is the amino acceptor, this step draws on a citric acid cycle intermediate and generates glutamate, which links the shunt to the glutamate pool. The first step of this pathway is production of glutamate from α-ketoglutarate. GABA-T is a reversible enzyme, so SSA can in principle be transaminated back to GABA. GABA-T catalyzes a reversible reaction, but SSADH activity is typically higher than that of GABA-T.

Oxidation to succinate

Succinic semialdehyde dehydrogenase (SSADH) oxidizes SSA to succinate and reduces NAD⁺ to NADH. This step is effectively one-way. The last step of the GABA shunt is catalyzed by succinic semialdehyde dehydrogenase, irreversibly oxidizing succinic semialdehyde to succinate. Because SSADH activity usually exceeds GABA-T activity, SSA tends not to build up under normal conditions. The succinate produced re-enters the cycle, where SSA is rapidly oxidized by SSADH, and it enters the TCA cycle as succinate.

Position and energetics of the shunt

The shunt is a detour around the cycle rather than an addition to it. It bypasses two successive steps of the tricarboxylic acid cycle catalyzed by α-ketoglutarate dehydrogenase and succinyl-CoA synthetase. The energy yield is lower. In the standard route from α-ketoglutarate to succinate, one ATP and one NADH are generated, whereas the shunt generates only one NADH. During metabolic conversion of α-ketoglutarate to succinate by the TCA cycle, one ATP and one NADH are generated, whereas the GABA shunt generates only one NADH.

The shunt also helps keep the GABA and glutamate pools in balance. Glutamate formed in mitochondria has to leave them to be used by the cytosolic decarboxylase, since GAD is a cytosolic enzyme, so glutamate needs to be exported from mitochondria, probably through known transporters. In plants, the shunt is strongly responsive to stress. The activity of the GABA shunt in plants is rapidly enhanced in response to various biotic and abiotic stresses.

Alternative fates of succinic semialdehyde

SSA has a second fate: reduction to γ-hydroxybutyrate (GHB). In mammalian brain, this reduction is carried out by a cytosolic, NADPH-dependent reductase. Both enzymes are localized in the cytosol and use NADPH as coenzyme, but differ in substrate specificity. SSA reductase exhibits pronounced specificity for SSA whereas aldehyde reductase acts on a great variety of aliphatic and aromatic aldehydes. The overall route from GABA to GHB therefore runs from a mitochondrial transamination to a cytosolic reduction. GABA is converted to SSA by GABA transaminase in mitochondria, followed by reduction of SSA to GHB by cytosolic succinic semialdehyde reductase.

The reverse conversion occurs in a different compartment. A mitochondrial enzyme can turn GHB back into SSA. In one study, the dialyzed mitochondrial fraction catalyzed the oxidation of GHB to SSA in a reaction that did not require added NAD+ or NADP+. The enzyme from the mitochondrial fraction which converts GHB to SSA appears to be distinct from the NADP+-dependent cytosolic oxidoreductase which catalyzes this reaction.

Compartmentalization is not identical across organisms. In plants, reports describe SSA reduction to GHB occurring in the mitochondrion or plastid through NADPH-dependent glyoxylate/SSA reductases, which conflicts with the cytosolic location in mammals. During development, the balance also shifts. In rat brain, there is a relative decrease in the reductive pathway of succinic semialdehyde catabolism during development leading to gamma-hydroxybutyrate synthesis, compared to the oxidative pathway leading to succinate.

When SSADH is impaired, SSA accumulates and is diverted toward GHB. This shift underlies the disorder discussed in the section on metabolic disorders. When blocked, accumulated SSA can be converted to gamma-hydroxybutyrate.

Storage, release, and clearance

Vesicular packaging

GABA in the terminal cytoplasm must be concentrated into synaptic vesicles before release, and this requires a dedicated carrier. VGAT belongs to a eukaryotic-specific superfamily whose members use H+-ATPase-driven uptake, followed by exocytotic release, of inhibitory amino acids. The transporter is also called VIAAT, and it is found in the vesicles of both GABAergic and glycinergic neurons. Consistent with its ability to transport either glycine or GABA, VIAAT is present in the synaptic vesicles of glycinergic and GABAergic neurons. Earlier biochemical work had suggested a separate vesicular glycine transporter, a question that the molecular cloning of VGAT helped to reframe. In studies carried out in support of the present invention, there was no significant uptake of 3H-glycine by the RUNC-47 PC-12 vesicle preparations, supporting the existence of a distinct vesicular transporter for glycine.

Immunolocalization places VGAT at the core of inhibitory terminals. VGAT is highly concentrated in the nerve endings of GABAergic neurons in the brain and spinal cord but also in glycinergic nerve endings. Notably, some GABA-containing terminals lack the transporter: hippocampal mossy fiber boutons, which although glutamatergic are known to contain GABA, lack VGAT immunoreactivity. Genetic evidence underlines its functional importance. Loss of Viaat causes a drastic reduction of neurotransmitter release in both GABAergic and glycinergic neurons, which indicates that glycinergic neurons do not rely on a separate vesicular glycine transporter.

Within a terminal, vesicles are organized into functional pools: a small group docked at release sites that can be discharged immediately, and larger reserve pools that replenish it during sustained firing. The partitioning of GABA-filled vesicles among these pools is less thoroughly mapped than the corresponding glutamate pools. In cortex, a minority of terminals carry both VGAT and the glutamate transporter VGLUT1, and vesicles at synapses expressing the vesicular heterotransporter participate in the exo-endocytotic cycle, which suggests some co-packaging of the two transmitters.

Calcium-dependent exocytosis

When an action potential invades the terminal, voltage-gated calcium channels open, and the resulting rise in intracellular calcium triggers fusion of vesicles with the presynaptic membrane through SNARE-dependent machinery, with synaptotagmin acting as the principal calcium sensor. GABA then diffuses across the synaptic cleft and binds postsynaptic receptors. Ionotropic GABA-A receptors open chloride-permeable channels, while metabotropic GABA-B receptors act through G proteins; both are described in the receptor section. Release is not limited to fully synchronous events, because spontaneous and asynchronous release also occur, and these modes contribute to tonic and background inhibition.

Reuptake and glial clearance

Synaptic signaling ends largely through removal of GABA from the extracellular space. GABAergic signals are terminated by the reuptake of neurotransmitters into nerve terminals or uptake into surrounding glia by plasma membrane GATs. Four GABA transporters have been cloned: three subtypes of high-affinity GAT (GAT-1, GAT-2, and GAT-3) and one lower-affinity betaine/glycine transporter that also transports GABA (BGT-1). These carriers are high-affinity, sodium ion (Na+), and Cl−-dependent transporters.

The transporters differ in cellular location. GAT1 is robustly expressed by neurons but is also expressed on astrocytes while GAT3 is largely localized to peri-synaptic astroglia. Regional patterns vary as well: in the rat globus pallidus, GAT-1 was preferentially expressed in unmyelinated axons, whereas GAT-3 was almost exclusively found in glial processes. Pharmacological blockade in that same study showed distinct effects: the GAT-1 inhibitor prolonged the decay of inhibitory currents without changing their amplitude, while the GAT-3 inhibitor increased amplitude and prolonged decay, and combined blockade had larger effects still. Reuptake into glia thus shapes both the duration and the strength of inhibition.

Glial uptake is a central part of this clearance. GAT-3 uptake mediates GABA reaccumulation in glial cells surrounding GABAergic synapses, thus contributing to both termination and regulation of GABAergic synaptic transmission. The direction of transport is debated: some reports describe reversal of GAT-1 during pathological activity, whereas others find that GABA transporter reversal does not occur even when presynaptic terminals populated with GAT-1 transporters generate trains of action potentials. The consensus is that normal physiological firing relies on forward uptake, with reversal at most transient under extreme conditions.

The glutamine–glutamate–GABA cycle

Because neurons cannot synthesize their transmitters de novo from glucose, they depend on astrocytes. Neurons are metabolically handicapped in the sense that they are not able to perform de novo synthesis of neurotransmitter glutamate and γ-aminobutyric acid (GABA) from glucose. The majority of glutamate, and a substantial fraction of GABA, released from neurons is recovered from the synapse by uptake into astrocytes. Within astrocytes, a portion of the captured GABA enters the TCA cycle to support glutamine synthesis.

Astrocytes then return glutamine to neurons, which is the metabolic basis of the cycle. Astrocytic glutamine is subsequently transferred to neurons, serving as the principal precursor for neuronal glutamate and GABA synthesis. Neuronal glutamate is converted to GABA by glutamic acid decarboxylase (covered in the biosynthesis section). The astrocytic glutamine export and neuronal uptake involve specific transporters: A similar intercellular cycle exists for GABA with distinct enzymes and transporters; in the case of the GABA system, the astrocyte glutamine transporter involved is primarily SNAT3 rather than SNAT5. Because this loop replaces transmitter carbon that is lost to oxidation and uptake, the cycle is also tied to energy metabolism: neurons must rely on astrocytes providing precursors for anaplerosis of the TCA cycle. Overall, the cycle is critical to maintaining the excitatory-inhibitory balance and is a prime example of intricate transcellular metabolic coupling within the brain.

GABA receptors and signaling mechanisms

GABA acts through three receptor classes. GABA-A and GABA-C are ligand-gated ion channels, while GABA-B is a metabotropic receptor that works through G proteins. The first two are both chloride-permeable pentamers, but they differ in subunit makeup and pharmacology.

GABA-A receptors as pentameric chloride channels

GABA-A receptors are heteropentamers, so five subunits assemble around a central pore. They are ligand-gated chloride channels that consist of pentameric combinations of different subunits. Subunit diversity is large. At least 19 subunit genes encode six α, three β, three γ, three ρ, and one each of δ, ε, π, and θ subunits, so the number of possible combinations is considerable. Each subunit has an extracellular N-terminal domain, four hydrophobic transmembrane domains (TM1–TM4) where TM2 lines the ion channel, and a large intracellular loop between TM3 and TM4. The pore-lining TM2 helices are arranged with close to fivefold symmetry, which explains the central location of the channel.

The most abundant receptor in the mammalian brain is built from two α1, two β2, and one γ2 subunit. The GABA binding sites lie at β2+/α1− interfaces, while the benzodiazepine modulatory site lies at α1+/γ2− interfaces. Receptor pharmacology and channel kinetics both depend on the subunit combination, and the receptors that sit in the extrasynaptic space tend to contain different subunits from those at synapses.

When GABA opens the channel, chloride ions move down their electrochemical gradient. In mature neurons intracellular chloride is kept low, so the chloride equilibrium potential is more negative than the resting membrane potential. Chloride influx therefore drives the membrane toward a more negative value, which hyperpolarizes the cell and makes it harder to reach threshold. Shunting inhibition, in which increased conductance reduces the effect of excitatory input even without large hyperpolarization, also contributes. The chloride gradient itself is maintained by transporters such as KCC2, and this gradient determines whether GABA is inhibitory or depolarizing in a given cell.

GABA-C receptors are built from ρ subunits. They are pharmacologically distinct: they are insensitive to bicuculline and baclofen, and they are often grouped with GABA-A receptors as GABA-A-ρ receptors in current nomenclature.

Modulatory sites and the historical evidence

GABA-A receptors carry several allosteric sites that change the response to GABA without themselves opening the channel. The best-known is the benzodiazepine site. Benzodiazepine-site agonists do not open the chloride channel directly but increase the capacity of GABA to do so.

The link between benzodiazepines and GABA was established in stages. In 1974, researchers at Roche and in the USA independently showed a highly specific potentiation of GABA by benzodiazepines. In 1977 benzodiazepines were found to bind a specific site in the CNS that proved to be part of the GABA-A receptor complex. Biochemical work in 1978 showed that GABA agonists increased benzodiazepine binding, and that this enhancement was blocked by the GABA antagonist (+)-bicuculline, while the (−) stereoisomer was much less active. Later purification experiments on benzodiazepine-affinity columns recovered a protein that carried both the GABA site and the benzodiazepine site. Subsequent work showed that both an α subunit and a β subunit are necessary structural components of GABA-A receptors. The GABA-A–benzodiazepine receptor was cloned in 1987. Taken together, these results showed that a behaviorally important part of benzodiazepine action comes from enhanced GABA signaling.

Barbiturates, neurosteroids, propofol, and volatile anesthetics also act at GABA-A receptors. Barbiturates and neurosteroids such as allopregnanolone bind distinct transmembrane sites and mainly prolong channel opening, whereas benzodiazepines increase the frequency of opening. Propofol and volatile anesthetics also modify GABA-A currents, and these drugs change GABA-A chloride currents in a subunit-specific manner. Because the response depends on subunit composition, the same drug can have different effects on receptors that contain different subunits.

GABA-B receptors and G-protein signaling

GABA-B receptors are heterodimers. They consist of one GABBR1 subunit and one GABBR2 subunit. GABBR1 binds GABA, while GABBR2 is needed for surface trafficking and for coupling to G proteins. GABBR1 binds the endogenous ligand, while GABBR2 controls trafficking to the cell surface and interacts with G proteins.

After receptor activation, the G protein releases its βγ subunits, which act on effectors directly. These βγ subunits are thought to inhibit Ca2+ channels and activate K+ channels. Postsynaptically, the resulting potassium conductance hyperpolarizes the cell. Presynaptically, reduced calcium entry lowers transmitter release. In the calyx of Held, for example, the GABA-B agonist baclofen suppressed EPSCs and presynaptic calcium currents without affecting voltage-dependent potassium currents.

GABA-B responses are slower and longer-lasting than GABA-A responses because they depend on second-messenger cascades rather than direct channel opening. Accessory proteins can also tune the timing; for instance, KCTD proteins associate with the C terminus of GB2 and shape the kinetics of GABA-B signaling by sequestering Gβγ subunits from GIRK channels. GABA-B receptors are also more often found away from the synaptic cleft than GABA-A receptors, and most GABA-B receptors are extrasynaptic, sometimes close to glutamatergic synapses.

Roles in neural circuits and brain function

Cell populations and their share of the cortex

Inhibitory cells make up roughly a fifth of neocortical neurons in many regions and species Approximately one in five neurons is GABAergic in many neocortical areas and species, forming a critical balance between inhibition and excitation in adult circuits. The estimate shifts with the brain area measured. One review places the share at 10%–25% of the total number of cortical neurons, depending on the brain region. Counts from rats and mice cluster near 15%, whereas primate studies more often report values above 20% Most of the studies performed in rat and mouse found that cortical GABAergic neurons represent around 15% (14–16%) of the overall population. In monkey and human their proportion mostly exceeds 20% (20–29%).

GABAergic cells are not a uniform class. Parvalbumin-expressing interneurons account for ∼40% of GABAergic neurons and include fast spiking basket cells and chandelier cells. Somatostatin-expressing interneurons, which include the Martinotti cells, form the next-largest group. Because most cortical neurons are excitatory, the majority of their postsynaptic targets are cells that GABA can quiet, so GABA acts as the principal brake on firing across the mature cortex.

Excitation–inhibition balance and rhythm

Cortical rhythms depend on the ratio between excitation and inhibition. In auditory cortex, interactions between excitatory and inhibitory neurons generate synchronous network gamma oscillations (30–70 Hz). Phasic GABA-A inhibition supplies the timing: gamma-frequency oscillations depend on phasic synaptic GABA-A receptor-mediated inhibition to synchronize spike timing. Extrasynaptic receptors add a second layer. Tonic inhibition of interneurons, mediated by δ-subunit-containing GABA-A receptors, counteracts the acceleration that NMDA receptor activation on those same interneurons would otherwise produce in hippocampal gamma rhythms The NMDAR-dependent increase of gamma oscillation frequency was counteracted by the tonic inhibition of the interneurons mediated by δ subunit–containing GABAARs.

In humans, these relationships have been probed with imaging. In one study, the endogenous resting concentration of GABA was positively correlated with the frequency of stimulus-induced gamma oscillations in medial occipital cortex. This is a correlation in healthy participants, not evidence that GABA alone sets gamma frequency. The balance itself also varies: measured cortical excitation–inhibition ratios shift across the day, a slow daily regulation of cortical excitation/inhibition balance, which depends on circadian-timing and prior sleep-wake history.

Motor control, sensory processing, arousal and sleep

Several major motor structures rely on GABAergic output. Cerebellar Purkinje cells are GABAergic and inhibit the deep cerebellar nuclei, while striatal projection neurons send GABAergic signals to the basal ganglia output nuclei, which regulate the thalamus and brainstem motor centers. In sensory pathways, the thalamic reticular nucleus is composed largely of GABAergic neurons that gate signals passing from the thalamus to the cortex. Lateral inhibition among cortical interneurons sharpens the selectivity of receptive fields, which is one reason GABA is considered essential for sensory discrimination.

Arousal and sleep are controlled in part by GABAergic cells. Many sleep-promoting neurons in the ventrolateral preoptic area are GABAergic and project onto arousal nuclei such as the tuberomammillary nucleus. Drugs that enhance GABA-A signaling therefore produce sedation, which is one reason the GABA system is a target in insomnia treatment.

The depolarizing phase in development

In immature neurons, GABA often has the opposite effect to the one seen in adults. NKCC1 is expressed at high levels in immature neurons, where it transports chloride into the cell, along with potassium and sodium. A concomitant low level of KCC2 expression keeps intracellular chloride levels high. The net result of this is that opening of GABA_A receptors results in an efflux of chloride, leading to neuronal depolarization. The chloride gradient, which is governed by the cation-chloride cotransporters, therefore determines whether GABA-A activation raises or lowers the membrane potential.

The developmental change comes from a switch in transporter expression. The subsequent ontogenetic switch, i.e., upregulation of the Cl−-extruder KCC2, with or without downregulation of NKCC1, results in low [Cl−]i levels and the hyperpolarizing action of GABA in mature neurons. The timing differs by region. Developmental shifts (decreases) in [Cl−]i parallel the maturation of the nervous system, e.g., early in the spinal cord, hypothalamus and thalamus, followed by the limbic system, and last in the neocortex. Before synapses form, GABA released from growth cones can act on neighboring cells through extrasynaptic receptors GABA released from growth cones diffuses in the extracellular space, binds to GABA_A receptors located on the membrane of a neighboring cell and depolarizes the membrane through an outwardly directed flux of chloride. Depolarizing GABA also supports network maturation: NKCC1-mediated Cl− accumulation contributes to GABAergic excitation and network activity during early postnatal development and thus facilitates the maturation of excitatory and inhibitory synapses. Depolarization is not always excitatory; there are counter-examples of GABA acting to depolarize cells leading to inhibition of network activity.

Roles beyond the nervous system

Pancreatic islets

GABA is unusually abundant in the pancreas. Endogenous GABA levels are highly enriched in the islet, as high as in the brain, and GABA is synthesized in and secreted from the beta cells. Insulin-secreting cells are thought to make most of the islet GABA, with glucagon-producing alpha cells possibly contributing a share. The storage route is disputed. Early work proposed synaptic-like microvesicles (analogous to synaptic vesicles in neurons) or co-secretion with insulin from large dense-core vesicles, and more recent studies suggest that beta cells lack the vesicular GABA transporter that neurons use. Instead, GABA leaves the cytosol in pulses through the LRRC8A/D volume-regulated anion channel.

GABA acts mainly in a paracrine manner on neighboring islet cells. In alpha cells, GABA activates GABA_A receptors, which causes chloride influx and membrane hyperpolarization and thereby suppresses glucagon release. The effect on beta cells is less clear-cut and depends on glucose. GABA stimulated insulin secretion at low glucose, but inhibited insulin secretion at high glucose. The sign of the response is set by the chloride equilibrium potential: in beta cells GABA_AR signaling can be excitatory in low glucose and inhibitory in high glucose, while in alpha cells GABA_AR signaling is inhibitory.

Endocrine function and diabetes

Because GABA regulates islet hormone output, it is often linked to diabetes. GAD was found to be one of the major autoantigens in T1D and GABA was found to be decreased in endocrine pancreatic tissue in experimental and human diabetes. Animal studies have produced mixed results. In streptozotocin-treated mice, treatment with GABA largely restored the immunodetectable levels of insulin and GAD in β cells, yet another study revealed that long-term administration of artesunate or GABA to mice did not stimulate α‐to‐β‐cell transdifferentiation or insulin secretion. A clinical trial in children with newly diagnosed type 1 diabetes has also been started to assess GABA's safety and effects, but the therapeutic role of GABA signaling remains unestablished.

Immune system

Immune cells appear to carry a complete GABAergic machinery. These studies confirm that immune cells possess all the molecular components of a GABAergic system. Indeed, they produce GABA and respond to this mediator in several assays, usually in an inhibitory way. In human CD4⁺ T cells, GABA decreased proliferation, and inhibited secretion of 37 cytokines in a concentration-dependent manner in responding cells. Cells from patients with type 1 diabetes showed a broader response. In anti-CD3 stimulated PBMCs, GABA (100nM) inhibited release of 47 cytokines in cells from patients with type 1 diabetes (T1D), but only 16 cytokines in cells from nondiabetic (ND) individuals.

The immunosuppressive effect also depends on metabolic context. Insulin appears to strengthen the GABA-mediated brake on T cells, whereas high glucose weakens it. At glucose concentrations that may be observed in diabetes, the inhibition normally provided by GABA is overrun and T cells-driven inflammation prevails. The field is not settled, and one review notes that despite these reports the topic remains controversial.

Plants

In plants, GABA is produced in large amounts during stress. Its accumulation occurs due to environmental stresses and attacks from pathogens and insects. Two functions are well supported. First, GABA helps regulate cytosolic pH. Since the GAD reaction consumes a proton, GABA might act as a pH regulator. Second, GABA links nitrogen and carbon metabolism. Under stress, Glu is catalyzed by GAD to rapidly synthesize GABA, which serves as an intermediary of plant nitrogen metabolism, allowing it to temporarily store nitrogen. The resulting succinate can re-participate in the TCA cycle through the formation of succinic semialdehyde and succinic acid.

GABA also appears in developmental and senescence programs. Reported roles include the elongation of pollen tubes, fruit ripening, root growth, and seed germination. During leaf senescence, nitrogen and carbon skeletons become again available to the metabolic system of the plant through the enhanced activity of the GABA shunt, in particular, GABA-T, based on studies of GABA-T mutants in Arabidopsis. Additional proposed functions include defense against insects and necrotrophic fungi, and in one account elevated GAD gene expression due to salt stress triggers extensive GABA synthesis.

Bacteria and other microorganisms

Many bacteria synthesize GABA, and the best-characterized role is acid resistance. Enteric bacteria such as Escherichia coli use a glutamate-dependent acid resistance system in which glutamate decarboxylase consumes an intracellular proton while converting glutamate to GABA, and a transporter then exports the GABA. This process raises the internal pH during acid challenge. Lactic acid bacteria, which are central to food fermentation, are also associated with GABA production, which is one reason microbial fermentation is used as an industrial route to GABA.

Disorders of GABA metabolism and clinical links

Inherited defects of GABA breakdown

Inherited disorders of GABA metabolism are rare. The best-characterized are GABA-transaminase deficiency, succinic semialdehyde dehydrogenase (SSADH) deficiency and homocarnosinosis. A fourth group, pyridoxine-dependent epilepsy, is sometimes listed here but is discussed in the biosynthesis section, since no defect in GABA production has been documented in it.

GABA-transaminase (GABA-T) deficiency is inherited as an autosomal recessive disorder, and it results from biallelic pathogenic variants in the ABAT gene. Affected infants typically show neonatal encephalopathy, epilepsy, hypotonia and intellectual disability. Laboratory findings center on the cerebrospinal fluid (CSF): elevated CSF GABA and beta-alanine support the diagnosis, which is then confirmed by enzyme measurement or molecular testing. Severe cases are often fatal in childhood. Since the first patients were described in 1984, only a small number of cases have been reported in the literature.

SSADH deficiency is the most common of these conditions. The enzyme is a mitochondrial enzyme whose activity is impaired, and when it fails, affected individuals accumulate large quantities of two neuroactive compounds in physiologic fluids: GABA and 4-hydroxybutyric acid (GHB). Clinically, the condition is a relatively non-progressive encephalopathy typically presenting with hypotonia and delayed motor and language milestones in the first two years of life. Seizures are seen in approximately 50% of patients. Neuropsychiatric features, including anxiety, obsessive-compulsive behavior and autistic-like traits, are common and tend to become more disabling with age. Diagnosis usually starts with increased gamma-hydroxybutyric aciduria on a urinary organic acid analysis, and is established by identifying biallelic variants in ALDH5A1. Reported case numbers differ across sources and over time, reflecting both changing ascertainment and the rarity of the disorder. Neuroimaging in a series of 30 patients revealed T2 hyperintensities most commonly in the globus pallidus. So far, there is no approved curative therapy for this disease.

Why CSF analysis is central

Both GABA-T deficiency and homocarnosinosis appear to be very rare, but require cerebrospinal fluid for detection, thus allowing for the possibility that these entities... are under-recognized. Measurements in blood or urine can be misleading, and the relevant metabolic changes are best captured in the fluid that bathes the brain. The pattern also helps separate the two conditions: the free and total GABA levels in cerebrospinal fluid are elevated, but there is no elevation in GHB levels in GABA-T deficiency, whereas SSADH deficiency is defined by large GHB increases. In SSADH deficiency, CSF metabolite profiles from 13 unrelated patients demonstrated significantly elevated GHB (65- to 230-fold), high free and total GABA (up to threefold), and low glutamine.

Homocarnosinosis

Homocarnosinosis involves homocarnosine, a dipeptide composed of GABA and histidine, which accumulates in the brain and CSF. The original description came from a Norwegian family in 1976, in which homocarnosine was elevated in the CSF, approximately 20 times the mean control level, in two brothers and one sister. Interpretation was complicated because the mother was clinically normal but had elevated CSF homocarnosine in a range even higher than that of the affected children. The enzymatic basis was reported as deficiency of homocarnosinase in the brain, and the broader picture links the disorder to serum carnosinase deficiency. The clinical picture described in the family, spastic paraplegia, progressive mental deficiency, and retinal pigmentation, has not been established as caused by the biochemical change. Only one family has been reported, so the association remains uncertain.

Reported links to congenital malformations

Impaired GABA synthesis has been associated with birth defects in limited data. One report notes that a recent link has also been made between impaired GABA synthesis and nonsyndromic cleft lip, with or without cleft palate. Specifically, linkage between GAD67 deficiency and nonsyndromic cleft lip and palate has been demonstrated. These findings are based on a small number of families and should be treated as preliminary, not as an established cause of orofacial clefts.

Autoimmunity against GAD

Autoantibodies directed against glutamic acid decarboxylase (GAD), especially the GAD65 isoform, are a separate clinical topic. They are characteristic of stiff-person syndrome, a rare neurological disorder marked by muscle rigidity and spasms, and they are found in a large share of individuals with type 1 diabetes, where they can appear years before the onset of hyperglycemia. In type 1 diabetes, GAD65 antibodies are used as a marker to identify people at risk and to help classify disease. Their pathogenic role in stiff-person syndrome is still debated, and attention has also turned to T-cell responses.

Associations with epilepsy, anxiety and schizophrenia

Altered GABAergic markers have been reported in several common brain disorders, but these are associations rather than established causes. In schizophrenia, postmortem studies have described reduced GAD67 expression in some cortical interneurons, and magnetic resonance spectroscopy has produced mixed GABA findings. Such results are confounded by medication, illness duration and small sample sizes, so they do not show that GABA deficiency drives the disorder. Benzodiazepines, which enhance GABA-A receptors, are effective treatments for anxiety, but this therapeutic effect does not demonstrate a primary GABA deficit in people with anxiety disorders. In epilepsy, variants in GABA-A receptor subunit genes are linked to specific inherited syndromes, whereas evidence for a general GABA deficit in common epilepsy is more limited. The strongest causal evidence comes from the inherited enzyme defects described above, not from these broader correlations.

Pharmacology: drugs that act on the GABA system

Positive allosteric modulators of GABA-A receptors

The largest group of GABA-related drugs does not bind at the GABA site itself. Benzodiazepines act on the GABA-A receptor, a pentameric chloride channel, by binding a regulatory site distinct from the GABA-binding pocket. In classical receptors, the high-affinity benzodiazepine site lies at the interface between an α and a γ subunit in the extracellular domain. Their effect is to increase how often the channel opens when GABA is already bound, so chloride enters the neuron more readily and the membrane becomes more hyperpolarized, which lowers firing. Barbiturates work at a different aspect of the same channel: they lengthen the time the pore stays open once opened, and at higher concentrations they can open it without GABA. Propofol and etomidate, widely used as intravenous anesthetics, also enhance GABA-A signaling through sites that differ from the benzodiazepine site.

Benzodiazepines are used for anxiety disorders, short-term treatment of insomnia, seizure control (clonazepam and diazepam are common anticonvulsants), muscle spasm, and seizure prophylaxis in alcohol withdrawal. Non-benzodiazepine hypnotics such as zolpidem, zopiclone and zaleplon bind the same benzodiazepine site, and the α1 subunit is linked to their sedative effects. Barbiturates have declined as anxiolytics and sedatives because of their narrow safety margin; they remain used for induction of anesthesia and in some refractory seizure settings. Because prolonged use of benzodiazepines produces tolerance and physical dependence, current guidance favors short courses. Chronic exposure is associated with downregulation of certain GABA-A subunits and compensatory changes in excitatory glutamatergic signaling. Newer agents, including partial modulators such as dimdazenil, are being developed to retain benefit while limiting excessive enhancement of receptor activity.

Inhibitors of GABA transaminase

Vigabatrin (γ-vinyl-GABA) is a structural analogue of GABA designed to inhibit GABA transaminase (GABA-T), the enzyme that degrades GABA to succinic semialdehyde. Because it binds the enzyme irreversibly, recovery of GABA-T activity depends on new enzyme synthesis, which takes several days. Blocking the breakdown raises GABA concentrations in the brain and in cerebrospinal fluid, which is the basis for its use as an add-on drug for refractory partial seizures and infantile spasms. It was first approved in the United Kingdom in 1989 and in the United States in 2009. Its main limitation is permanent visual field constriction, which requires careful monitoring; this toxicity also restricts its use in adults with other seizure types, and it is not a first-line agent in most settings.

Inhibitors of the GAT-1 transporter

Tiagabine is a derivative of nipecotic acid that selectively blocks GAT-1, the principal GABA transporter on presynaptic terminals. By slowing reuptake, it prolongs inhibitory postsynaptic potentials in hippocampal pyramidal cells without changing their amplitude, and it can also raise ambient GABA, producing a sustained tonic inhibition. Because the drug also affects GABA uptake by glial cells, its effects are not confined to the synapse. It is approved in the United States as an adjunctive treatment for partial seizures in adults and children aged 12 and older. Common adverse effects include drowsiness, dizziness and impaired concentration. Reports of new-onset seizures, including absence seizures, have been associated with use outside approved indications, and off-label use for anxiety and neuropathic pain has been explored but is not established.

GABA-B receptor agonists and related ligands

Baclofen, the R-enantiomer of a GABA analogue, is the classic clinical GABA-B agonist. It acts on the heterodimeric GABA-B receptor, a G-protein-coupled receptor that opens potassium channels and inhibits presynaptic calcium channels, reducing transmitter release in the spinal cord and brain. Baclofen is used as a muscle relaxant to treat spasticity arising from multiple sclerosis and spinal cord injury; it can be given orally or delivered intrathecally by pump for severe cases. Abrupt withdrawal can provoke hallucinations, seizures and rebound spasticity, so dosing is tapered. Beyond baclofen, research has focused on GABA-B positive allosteric modulators, which enhance the response to endogenous GABA without activating the receptor directly. Such compounds are being studied for their potential to produce fewer side effects than direct agonists. It should be noted that gabapentin and pregabalin, although structurally GABA-like, act mainly on the α2δ subunit of voltage-gated calcium channels rather than on GABA receptors.

Antagonists used in laboratory research

Pharmacological tools have been essential for separating GABA-A and GABA-B signaling. Bicuculline, a plant alkaloid, is a competitive antagonist that competes with GABA at its binding site on the GABA-A receptor. Its convulsant properties limit in vivo use, so more selective competitive antagonists such as gabazine are often preferred in electrophysiology. Picrotoxin, by contrast, is a non-competitive channel blocker that lodges within the chloride pore, so it reduces current regardless of how much GABA is bound. Flumazenil antagonizes benzodiazepine-site ligands without strongly altering GABA-evoked currents on its own. For GABA-B, phaclofen and saclofen serve as competitive antagonists, and CGP55845 is a potent and widely used antagonist in slice experiments. Comparing responses to these agents has helped establish whether a given inhibitory current is mediated by GABA-A or GABA-B receptors, and whether it depends on a binding site or on the channel itself.

Production, food, and supplement applications

Microbial and industrial production

Most GABA used commercially is made by microbes rather than by chemical synthesis. GABA has mostly been produced in lactic acid bacteria by adding L-glutamate to the culture medium, because the bacteria's own glutamate decarboxylase can convert it. Lactic acid bacteria (LAB) are favored for this work because they are categorized as generally regarded as safe and have long been used in fermented foods such as cheese, yogurt and beverages. The bacterial system pairs the enzyme with a transporter: glutamate is taken into the cell through GadC, and the decarboxylated product GABA is exported by the same transporter. Because each conversion consumes an intracellular proton, the pathway helps cells maintain internal pH under acid stress (contributing to intracellular pH homeostasis), which is also why yields depend strongly on conditions. In Lactococcus lactis, for example, glutamate decarboxylation was limited to narrow environmental conditions, namely pH below 5.1 and the stationary growth phase. Adding arginine raised output further, reaching 8.6 mM when arginine and glutamate were supplied together.

Strain engineering has pushed yields much higher. In one study, an engineered Lactobacillus brevis strain overexpressing two GAD genes reached 104.38 g/L at 72 h under a two-stage pH and temperature-controlled fed-batch fermentation. Outside LAB, researchers have expressed a mutant Escherichia coli GAD that remains active over a wider pH range in Corynebacterium glutamicum, a strain used industrially for glutamate production, so that GABA could be made directly from glucose. Their best reported titer for this approach was up to 26 g/L. The industrial interest is partly chemical: GABA is a potential building block for 2-pyrrolidone and for biodegradable polyamide nylon 4, which places it in biotechnology beyond food.

Accumulation in germinated grains, tea, and other foods

GABA is present in many plant foods, and its level can be raised deliberately. GABA levels rise rapidly in plants responding to various stresses, including anaerobic conditions. Germinated brown rice is the most studied example. Cold stress combined with germination produced a maximum of 195.64 mg/100 g in black rice grains, 51.54% higher than the control. Repeated soaking and incubation during germination reached 116.88 ± 9.24 mg/100 g of germinated brown rice on a dry basis in one report. Other treatments include heating and humidifying: in one study, the highest value was 258.03 mg/kg in paddy obtained at 65 °C, 20% humidity and 5 h, with GABA mainly produced in the germ and then migrating inward.

Mechanistically, the GAD enzyme in plant tissue is sensitive to conditions. During germination of brown rice, GAD is activated in the bran and germ, especially under slightly acidic and warm conditions (pH 5.5 and 40 °C). Anaerobic treatment has produced large effects; one study using CO2 or N2 gas found that GABA content could be raised more than 20 times. Stress does not always produce a monotonic increase. Prolonged stress may suppress GAD while GABA-T consumes accumulated GABA, so the observed increase followed by a decrease suggests a balance between GABA biosynthesis and its degradation under processing-induced stress. Varietal differences are large; in one study, the cultivar with the highest GABA content among nine tested was selected for further optimization. Similar strategies have been applied to tea and to legumes such as hyacinth bean, which has been proposed as a raw material for GABA-enriched germinated tea.

Regulatory status and labeling

GABA's legal status varies widely, and the descriptions in different sources do not fully agree. In the United States, GABA as an amino acid meets the definition of a dietary ingredient, and it appears on a pre-1994 industry list of ingredients already on the market. The FDA's food-additive database also lists it for technical use, as a flavoring agent or adjuvant. The number of labeled products has grown: as of 17 November 2025, the Dietary Supplement Label Database listed 1883 products declaring GABA on their labels, compared with 644 in April 2021.

Elsewhere the framework differs. In Canada, GABA is recognized as a medicinal ingredient, which places its products under natural health product licensing. In Asia, regulatory bodies in China, Japan, South Korea, Thailand, Vietnam and the Philippines recognize the use of GABA as a food or functional ingredient under defined conditions. In Europe, the picture is less consistent. One review describes GABA as an ingredient in food supplements, while a trade analysis states that in many countries in the EU, the sale of pure GABA is not allowed. A separate source describes GABA as a new food ingredient needing specific authorization. Gene-edited GABA-rich tomato lines have also been cleared for food use in some Asian markets; in Singapore, the approval exempted the crop from genetically modified organism pre-market authorization, and the same tomato line has been approved under similar provisions in the Philippines.

Whether dietary GABA reaches the brain

The question of whether dietary GABA has central effects is unresolved. GABA is a poorly penetrating molecule with respect to the blood–brain barrier, so the central effects reported after oral intake are debated. Studies of oral intake show a short-lived effect in blood: in one study comparing supplements with tomato juice, both forms temporarily increased plasma GABA levels, but concentrations returned to baseline within hours. A review of oral administration notes that although there is substantial evidence indicating that orally ingested GABA may affect GABA receptors in peripheral tissues, there is comparatively less evidence supporting its direct action within the brain. Proposed routes into central effects therefore centre on indirect signalling, including the gut-brain axis; emerging evidence highlights that oral GABA intake may exert beneficial effects on the brain and psyche through the gut–brain axis, though this evidence remains preliminary.

Discovery and research history

Identification in brain tissue (1950–1957)

The first report of GABA in the mammalian brain came in 1950. Eugene Roberts and Sam Frankel identified it as a major amine of brain tissue that the organ itself produces and preferentially accumulates. An abstract was submitted to the Federation meetings in March of 1950 reporting the presence of GABA in brain, and three papers dealing with the occurrence of GABA in brain appeared later that year in the same issue of the Journal of Biological Chemistry. Other groups reached the same conclusion independently, so that its presence in the brain was discovered independently by three groups in the year 1950.

The initial reception was cautious. In the five years following Roberts and Frankel's report, according to PubMed only four additional studies of GABA in the brain were published. For several years the compound remained a biochemical curiosity and a physiological enigma. Researchers lacked fast methods to test what it did, and the functional question was not settled until the late 1950s.

Physiological evidence for inhibition (1957–1960s)

The decisive functional step came in 1957. GABA's activity in the brain was clarified in 1957 when researchers in Canada reported that an unknown compound having inhibitory activity on crayfish neurons was, in fact, GABA. Over the following decade, electrophysiologists applied GABA directly to cat spinal cord and cerebral cortical neurons and observed that it reduced their firing, which established inhibition as its typical action in the mammalian central nervous system. In parallel, Roberts's group developed antisera against glutamic acid decarboxylase (GAD), the synthetic enzyme, and pioneered the immunohistochemical localization of neurotransmitter-specific neural systems at the light and electron microscopic levels. This work made it possible to map GABAergic neurons anatomically rather than only measuring GABA in bulk tissue.

Benzodiazepine sites and the GABA-A receptor (1974–1980s)

Pharmacology linked GABA to a second system in the 1970s. Following the clinical impact of the first benzodiazepines in the mid-1950s considerable effort went into investigating their mechanism of action. It was not until 1974 that researchers at Roche and in the USA independently showed that there was a highly specific potentiation of gamma-aminobutyric acid (GABA) by benzodiazepines. In 1977, two groups reported specific, high-affinity benzodiazepine binding sites in the brain, including the work of Möhler and Okada in Proc. Natl. Acad. Sci. USA and in Science. Subsequent work showed that the site turned out to be an integral part of the GABA_A receptor complex.

The link to GABA was then tested directly. The observation that BZs enhance the inhibitory action of GABA led researchers to determine that the target was the GABA receptor. The benzodiazepine site is therefore an allosteric modulatory site rather than the agonist site, and agonists binding to the benzodiazepine receptor site do not open the chloride channel directly, but rather augment the capacity of GABA to do so. Later, drugs which bind to it, yet have the opposite effects to the classical benzodiazepine receptor agonists were found, and these are now termed inverse agonists. Separately, GABA-B receptors were distinguished from GABA-A receptors on pharmacological grounds in the early 1980s; their genes were cloned only in the late 1990s.

Molecular cloning of receptor subunits (1987–1990s)

The GABA-A receptor was cloned in 1987. Investigators purified the receptor using benzodiazepine-affinity chromatography, derived partial amino acid sequences, and used them to design probes. GABA(A) receptors were also cloned in 1987, via low-stringency hybridization screening based on oligonucleotide sequence derived from the partial amino acid sequence of a protein purified by benzodiazepine-affinity chromatography. The resulting α and β subunits could be expressed outside the nervous system as a functional GABA receptor, and they belonged to a receptor family that included nicotinic acetylcholine and glycine receptors.

A surprise followed. Given that GABA_A receptor protein was purified by benzodiazepine affinity chromatography, the cloned αβ GABA receptor lacked sensitivity to benzodiazepines. The missing element was a third subunit. Work in 1989 identified a novel subunit that was important for benzodiazepine pharmacology, which is now known as the γ subunit. Over the following years the list of subunit genes expanded considerably; in the human genome, there are as many as 24 genes encoding ILGIC subunits, consisting of 19 GABA_A receptor (GABR) and 5 GlyR genes.

Later milestones

Clinical and pharmacological milestones after the cloning era, including drugs that target GABA transaminase and the GAT-1 transporter, are discussed in the pharmacology section, and the autoimmune and disease-related findings are covered elsewhere in this entry.

Open questions and current research directions

Tonic and extrasynaptic GABA signaling

Classical models treated GABA as a fast, synaptic signal, but the recognition of tonic inhibition has complicated that picture. Researchers attribute this sustained background suppression to extrasynaptic GABA-A receptors that respond to low, ambient GABA concentrations, in contrast to the brief, precisely timed currents of synaptic (phasic) inhibition. Synaptic (phasic) inhibition is spatially and temporally precise compared with tonic inhibition, which provides blunt yet strong integral inhibitory force by shunting electrical signaling. The receptors that carry tonic currents are pharmacologically distinct from synaptic ones: they tend to bind GABA with high affinity and desensitize slowly. The boundary between the two modes is not absolute. Strong synaptic firing can allow released GABA to escape the cleft and activate perisynaptic receptors, so the functional separation of phasic and tonic signaling depends on context.

The clinical relevance of tonic signaling is also unsettled. In temporal lobe epilepsy models, tonic currents appear largely preserved even as synaptic inhibition is often reduced, which has made tonic inhibition an attractive antiepileptic target. The network consequences of globally raising extracellular GABA are difficult to predict without knowing how epileptogenesis changes the pharmacology and GABA sensitivity of tonic inhibition. Long-term loss of extrasynaptic activity may also be offset by homeostatic adjustments in neuronal excitability. More recently, activity-dependent relocalization of tonic-receptor subunits into the synaptic cleft has been reported in several models, but its occurrence, mechanism, and functional meaning remain contested.

Heterogeneity of GABA-A receptor subtypes

GABA-A receptors are assembled from a large family of subunits; one review lists at least 18 subunits (α1–6, β1–3, γ1–3, δ, ε, θ, ρ1–3). Based on an in vivo point mutation strategy, α1-GABA-A receptors were found to mediate sedation, anterograde amnesia, and part of the seizure protection, whereas α2-GABA-A receptors, but not α3-receptors, mediate anxiolysis. Primate experiments point in a similar direction: α1 receptors do not appear to play a key role in the anxiolytic and muscle-relaxant properties of benzodiazepine-type drugs, which instead seem to involve α2, α3, and/or α5 subtypes. Such findings suggest that subtype-selective compounds could separate therapeutic effects from sedation and dependence, although this idea has not yet been fully tested in clinical use.

The heterogeneity seen at the molecular level is not always visible in physiological recordings. Significantly less heterogeneity has been found at the physiological level in native receptors, where the subunit combinations have been difficult to dissect. In cultured hippocampal neurons, two drugs acting on extrasynaptic receptors produced three distinct response patterns, which the authors interpreted as evidence for heterogeneous receptor populations. A central open question is how subtypes co-exist within individual cells and how this composition predicts an individual's response to a given drug.

Non-neuronal roles in cancer

Evidence that GABA signaling influences tumor biology has grown, but its direction and strength vary considerably between studies. Enzymes of GABA metabolism have been implicated in tumor behavior: GAD67 and ABAT, the key enzymes in GABA metabolism, are involved in regulating cancer proliferation and migration through their activities in GABA synthesis and degradation. Reported effects of GABA-B receptor activation on tumor cells include apoptosis in cell lines, with proposed pathways involving β-arrestins and JNK signaling. However, the effects are not uniform. In one study, a GABA-B antagonist reduced the proliferation of a chondrosarcoma cell line, which suggests that the outcome depends on the receptor subtype, the cell type, and the signaling context. Similarly, in a GABA-A receptor study, GABA slightly affected the proliferation of different cancer cells, and the effect in some lines was reversed by picrotoxin, a GABA-A channel blocker.

Several questions remain unresolved. Much of the evidence comes from cultured cell lines, and the translation to in vivo tumor models and patients is limited. Experimental designs, concentrations, and receptor-blocking controls differ widely, which makes cross-study comparison difficult. It is therefore unclear which of the reported effects on proliferation and cell death will prove reproducible and clinically meaningful.

Glial and gut-linked GABA metabolism

Two areas remain comparatively underexplored. The first is how GABA metabolism in glia contributes to brain health and disease. Astrocytes take up GABA and process it through metabolic routes that connect with the wider cycle of glutamate and glutamine, but how changes in these glial pathways affect neuronal inhibition under pathological conditions is still unclear. The second is the gut. Microorganisms and enteric cells can produce or respond to GABA, and the question of whether such gut-derived GABA influences the brain through peripheral routes remains open, partly because of the blood–brain barrier. Resolving these questions will require approaches that measure GABA flux in specific cell populations rather than in bulk tissue.

References

1. Effects of Oral Gamma-Aminobutyric Acid (GABA) Administration on Stress and Sleep in Humans: A Systematic Review - PMCpmc.ncbi.nlm.nih.gov
2. 4-Aminobutyric acidchemicalbook.com
3. An Updated Review on Pharmaceutical Properties of Gamma-Aminobutyric Acid - PMCpmc.ncbi.nlm.nih.gov
4. Gamma-aminobutyric acid - New World Encyclopedianewworldencyclopedia.org
5. Frontiersfrontiersin.org
6. Transport properties of Gamma-Aminobutyric Acid in waterarxiv.org
7. Insights and progress on the biosynthesis, metabolism, and physiological functions of gamma-aminobutyric acid (GABA): a reviewncbi.nlm.nih.gov
8. 4-Aminobutyric acid: Structure and Function_Chemicalbookchemicalbook.com
9. Application and progress of glutamate decarboxylase in industrial biotechnologylink.springer.com
10. Treatment of cocaine addictionimage-ppubs.uspto.gov
11. Crystals of human glutamic acid decarboxylase 65 (GAD65)image-ppubs.uspto.gov
12. Compartmentalization of GABA Synthesis by GAD67 Differs between Pancreatic Beta Cells and Neuronsjournals.plos.org
13. Glutamate Decarboxylase 65 - an overviewsciencedirect.com
14. Glutamate Decarboxylase 67 - an overviewsciencedirect.com
15. 4 Aminobutyric Acid Metabolism - an overviewsciencedirect.com
16. Glutamate decarboxylaseen.wikipedia.org
17. Cofactor-dependent conformational heterogeneity of GAD65 and its role in autoimmunity and neurotransmitter homeostasispnas.org
18. Brain Glutamate Decarboxylaselink.springer.com
19. Glutamate Decarboxylase from Lactic Acid Bacteria—A Key Enzyme in GABA Synthesisncbi.nlm.nih.gov
20. REVIEW The versatile GABA in plants Li Li, Na Dou, Hui Zhang, and Chunxia Wuscienceopen.com
21. Nitrogen use efficient transgenic plantsimage-ppubs.uspto.gov
22. Mitochondrial succinic-semialdehyde dehydrogenase of the γ-aminobutyrate shunt is required to restrict levels of reactive oxygen intermediates in plantspnas.org
23. Catabolism of GABA, succinic semialdehyde or gamma-hydroxybutyrate through the GABA shunt impair mitochondrial substrate-level phosphorylation - ScienceDirectsciencedirect.com
24. Cloning and expression of succinic semialdehyde reductase from human brain - Schaller - 1999 - European Journal of Biochemistry - Wiley Online Libraryfebs.onlinelibrary.wiley.com
25. Succinate Semialdehyde Dehydrogenase - an overviewsciencedirect.com
26. (PDF) Oxidation of γ‐Hydroxybutyrate to Succinic Semialdehyde by a Mitochondrial Pyridine Nucleotide‐Independent Enzymeacademia.edu
27. Ontogeny and distribution of specific succinic semialdehyde reductase apoenzyme in the rat brain - PubMedpubmed.ncbi.nlm.nih.gov
28. Succinic Semialdehyde Dehydrogenase: Biochemical–Molecular–Clinical Disease Mechanisms, Redox Regulation, and Functional Significanceresearchgate.net
29. Mutants of GABA Transaminase (POP2) Suppress the Severe Phenotype of succinic semialdehyde dehydrogenase (ssadh) Mutants in Arabidopsisncbi.nlm.nih.gov
30. Succinic Semialdehyde - an overviewsciencedirect.com
31. (A) Alternative pathways for GABA metabolism via succinic semialdehyde....researchgate.net
32. Vesicular Inhibitory Amino Acid Transporter - an overviewsciencedirect.com
33. The mouse vesicular inhibitory amino acid transporter gene: Expression during embryogenesis, analysis of its core promoter in neural stem cells and a reconsideration of its alternate splicing - ScienceDirectsciencedirect.com
34. Vesicular amino acid transporter composition and methodimage-ppubs.uspto.gov
35. The Vesicular GABA Transporter, VGAT, Localizes to Synaptic Vesicles in Sets of Glycinergic as Well as GABAergic Neuronsjneurosci.org
36. A Shared Vesicular Carrier Allows Synaptic Corelease of GABA and Glycine: Neuroncell.com
37. GABA Transporter 1 - an overviewsciencedirect.com
38. GABA Transporter 3 - an overviewsciencedirect.com
39. Regulated Trafficking of GABA Transporters, GAT1 and GAT3, in Response to Methamphetamine - ScienceDirectsciencedirect.com
40. pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov
41. GAT-3, a High-Affinity GABA Plasma Membrane Transporter, Is Localized to Astrocytic Processes, and It Is Not Confined to the Vicinity of GABAergic Synapses in the Cerebral Cortexjneurosci.org
42. Synaptic GABA release prevents GABA transporter type-1 reversal during excessive network activitynature.com
43. The glutamate/GABA‐glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer - Bak - 2006 - Journal of Neurochemistry - Wiley Online Libraryonlinelibrary.wiley.com
44. Milestone Review: Metabolic dynamics of glutamate and GABA mediated neurotransmission — The essential roles of astrocytes - Andersen - 2023 - Journal of Neurochemistry - Wiley Online Libraryonlinelibrary.wiley.com
45. The Glutamate/GABA‐Glutamine Cycle: Insights, Updates, and Advancesncbi.nlm.nih.gov
46. The Glutamate/GABA‐Glutamine Cycle: Insights, Updates, and Advances - Andersen - 2025 - Journal of Neurochemistry - Wiley Online Libraryonlinelibrary.wiley.com
47. Glutamate-Glutamine Cycle - an overviewsciencedirect.com
48. GAT-1 and reversible GABA transport in Bergmann glia in slicesresearchgate.net
49. Glutamine-Glutamate Cycle Flux Is Similar in Cultured Astrocytes and Brain and Both Glutamate Production and Oxidation Are Mainly Catalyzed by Aspartate Aminotransferasemdpi.com
50. GABAA receptors: structure, function, pharmacology, and related disorderslink.springer.com
51. GABAA Receptor - an overviewsciencedirect.com
52. The Benzodiazepine Binding Sites of GABA A Receptorsresearchgate.net
53. New insights into the role of the GABAA–benzodiazepine receptor in psychiatric disordercambridge.org
54. Certain fused pyrrolecarboxanilides; a new class of gaba brain receptor ligandsimage-ppubs.uspto.gov
55. Benzodiazepine Receptor - an overviewsciencedirect.com
56. β subunits of GABAA receptors form proton-gated chloride channels: Insights into the molecular basis - PMCpmc.ncbi.nlm.nih.gov
57. GABA Receptor - an overviewsciencedirect.com
58. Gamma-amino-butyric acid derivatives as GABAB receptor ligandsimage-ppubs.uspto.gov
59. GABAB receptor modulation of synaptic function - PMC - NIHpmc.ncbi.nlm.nih.gov
60. G-Protein-Coupled Modulation of Presynaptic Calcium Currents and Transmitter Release by a GABAB Receptorjneurosci.org
61. Molecular mechanisms of metabotropic GABAB receptor functionscience.org
62. Expression and purification of a functional heteromeric GABAA receptor for structural studiesncbi.nlm.nih.gov
63. The Benzodiazepine Binding Sites of GABAA Receptors - ScienceDirectsciencedirect.com
64. A structural perspective on GABAA receptor pharmacology - ScienceDirectsciencedirect.com
65. GABAB Receptors Couple to Potassium and Calcium Channels on Identified Lateral Perforant Pathway Projection Neuronsjournals.physiology.org
66. The Fraction of Cortical GABAergic Neurons Is Constant from Near the Start of Cortical Neurogenesis to Adulthoodjneurosci.org
67. GABAergic Interneurons Shape the Functional Maturation of the Cortex - ScienceDirectsciencedirect.com
68. Neocortical calretinin neurons in primates: increase in proportion and microcircuitry structurencbi.nlm.nih.gov
69. Three groups of interneurons account for nearly 100% of neocortical GABAergic neurons - Rudy - 2011 - Developmental Neurobiology - Wiley Online Libraryonlinelibrary.wiley.com
70. Spatial Profile and Differential Recruitment of GABAB Modulate Oscillatory Activity in Auditory Cortexjneurosci.org
71. Control of hippocampal gamma oscillation frequency by tonic inhibition and excitation of interneuronsnature.com
72. Resting GABA concentration predicts peak gamma frequency and fMRI amplitude in response to visual stimulation in humanspnas.org
73. Circadian dynamics in measures of cortical excitation and inhibition balancencbi.nlm.nih.gov
74. Introductionfrontiersin.org
75. Development and regulation of chloride homeostasis in the central nervous systemncbi.nlm.nih.gov
76. Functional role of ambient GABA in refining neuronal circuits early in postnatal developmentncbi.nlm.nih.gov
77. NKCC1-Dependent GABAergic Excitation Drives Synaptic Network Maturation during Early Hippocampal Developmentjneurosci.org
78. Development and specification of GABAergic cortical interneuronslink.springer.com
79. The role of GABA in islet functionfrontiersin.org
80. Biosensor Cell Array Reveals Temporal GABA Secretion Dynamics from Pancreatic Islets - PMCpmc.ncbi.nlm.nih.gov
81. Gamma-aminobutyric acid up- and downregulates insulin secretion from beta cells in concert with changes in glucose concentrationlink.springer.com
82. Methods for producing a population of pancreatic beta-cellsimage-ppubs.uspto.gov
83. Pancreatic Islet Cell Hormones: Secretion, Function, and Diabetes Therapy - PMCpmc.ncbi.nlm.nih.gov
84. Immunological GABAergic interactions and therapeutic applications in autoimmune diseases - ScienceDirectsciencedirect.com
85. GABA Regulates Release of Inflammatory Cytokines From Peripheral Blood Mononuclear Cells and CD4+ T Cells and Is Immunosuppressive in Type 1 Diabetes - eBioMedicinethelancet.com
86. GABA-mediated inhibition of human CD4+ T cell functions is enhanced by insulin but impaired by high glucose levels - eBioMedicinethelancet.com
87. RESEARCH ARTICLE Activation of GABA(A) receptors inhibits T cell proliferationjournals.plos.org
88. Plant-derived gamma-aminobutyric acid (GABA): Role in stress responses, growth, metabolism, and therapeutic potential for neuropsychiatric disorders - ScienceDirectsciencedirect.com
89. Why did glutamate, GABA, and melatonin become intercellular signalling molecules in plants?elifesciences.org
90. Role of Gamma-Aminobutyric Acid in Plant Defense Response - PMCpmc.ncbi.nlm.nih.gov
91. Full article: The effects of GABA in plantstandfonline.com
92. GABA in plants: Just a metabolite?researchgate.net
93. GABA Coordinates with Insulin in Regulating Secretory Function in Pancreatic INS-1 β-Cellsncbi.nlm.nih.gov
94. A randomized trial of oral gamma aminobutyric acid (GABA) or the combination of GABA with glutamic acid decarboxylase (GAD) on pancreatic islet endocrine function in children with newly diagnosed type 1 diabetesnature.com
95. Activation of GABA(A) receptors inhibits T cell proliferationjournals.plos.org
96. Inherited disorders of GABA metabolism - PMC - NIHpmc.ncbi.nlm.nih.gov
97. GABA-transaminase deficiencymedlink.com
98. Identification of Additional Cases of Severe Neonatal GABA‐Transaminase Deficiencyncbi.nlm.nih.gov
99. GABA TRANSAMINASE DEFICIENCY WITH SURVIVAL INTO ADULTHOOD - PMCpmc.ncbi.nlm.nih.gov
100. Succinic Semialdehyde Dehydrogenase Deficiency: An Updatencbi.nlm.nih.gov
101. Entry - #271980 - SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY; SSADHD - OMIM - (OMIM.ORG)omim.org
102. Succinic Semialdehyde Dehydrogenase Deficiency - GeneReviews® - NCBI Bookshelfncbi.nlm.nih.gov
103. Succinic Semialdehyde Dehydrogenase Deficiency - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
104. Succinic semialdehyde dehydrogenase deficiencymedlink.com
105. Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiencycdn.clinicaltrials.gov
106. GABA Receptor - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
107. HOMOCARNOSINOSIS. 2. A FAMILIAL METABOLIC DISORDER ASSOCIATED WITH SPASTIC PARAPLEGIA, PROGRESSIVE MENTAL DEFICIENCY, and RETINAL PIGMENTATION - Sjaastad - 1976 - Acta Neurologica Scandinavica - Wiley Online Libraryonlinelibrary.wiley.com
108. Entry - 236130 - HOMOCARNOSINOSIS - OMIM - (OMIM.ORG)omim.org
109. Inherited disorders of GABA metabolismlink.springer.com
110. Homocarnosinosis. 2. A familial metabolic disorder associated with spastic paraplegia, progressive mental deficiency, and retinal pigmentation - PubMedpubmed.ncbi.nlm.nih.gov
111. 2-Pyrrolidinone and Succinimide as Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosisncbi.nlm.nih.gov
112. Disorders of GABA metabolism: SSADH and GABA-transaminase deficiencies - PMCpmc.ncbi.nlm.nih.gov
113. GABA transaminase deficiency. Case report and literature review - Oshi - 2021 - Clinical Case Reports - Wiley Online Libraryonlinelibrary.wiley.com
114. Clinical features and ALDH5A1 gene findings in 13 Chinese cases with succinic semialdehyde dehydrogenase deficiencyncbi.nlm.nih.gov
115. Homocarnosinosis Author: Professor Jaak Jaeken1 Creation Date: September 2001orpha.net
116. Clinical aspects of the disorders of GABA metabolism in children - PubMedpubmed.ncbi.nlm.nih.gov
117. GABA Receptor Positive Allosteric Modulatorsstatpearls.com
118. Progress in GABAA receptor agonists for insomnia disorderncbi.nlm.nih.gov
119. Novel positive allosteric modulators of GABAA receptors with anesthetic activityncbi.nlm.nih.gov
120. Allosteric Modulators of GABAB Receptors: Mechanism of Action and Therapeutic Perspective - PMCpmc.ncbi.nlm.nih.gov
121. Benzodiazepine Dependence: Clinical and Molecular Aspects, Preventive Strategies and Therapeutic Approachesncbi.nlm.nih.gov
122. Structural and dynamic mechanisms of GABAA receptor modulators with opposing activitiesncbi.nlm.nih.gov
123. Vigabatrin: Uses, Interactions, Mechanism of Actiongo.drugbank.com
124. Molecular Basis of GABA Aminotransferase Inhibition in Epilepsy: Structure, Mechanisms, and Drug Developmentncbi.nlm.nih.gov
125. Vigabatrin - an overviewsciencedirect.com
126. Tiagabine - an overviewsciencedirect.com
127. Seizure Activity and Off-Label Use of Tiagabineresearchgate.net
128. Full article: Ways of modulating GABA transporters to treat neurological diseasetandfonline.com
129. Synaptic and extrasynaptic GABA transporters as targets for anti-epileptic drugs - PubMedpubmed.ncbi.nlm.nih.gov
130. Antiepileptic Drug Tiagabine Does Not Directly Target Key Cardiac Ion Channels Kv11.1, Nav1.5 and Cav1.2ncbi.nlm.nih.gov
131. Enhanced production of gamma-aminobutyrate (GABA) in recombinant Corynebacterium glutamicum by expressing glutamate decarboxylase active in expanded pH rangencbi.nlm.nih.gov
132. Overexpression and optimization of glutamate decarboxylase in Lactobacillus plantarum Taj-Apis362 for high gamma-aminobutyric acid productionncbi.nlm.nih.gov
133. Production of Gamma-Aminobutyric Acid from Lactic Acid Bacteria: A Systematic Reviewncbi.nlm.nih.gov
134. Exploring the contributions of two glutamate decarboxylase isozymes in Lactobacillus brevis to acid resistance and γ-aminobutyric acid productionmicrobialcellfactories.biomedcentral.com
135. GABA Production in Lactococcus lactis Is Enhanced by Arginine and Co-addition of Malatencbi.nlm.nih.gov
136. (PDF) Enhancing gamma-aminobutyric acid content in germinated brown rice by repeated treatment of soaking and incubationresearchgate.net
137. Accelerated Accumulation of γ-Aminobutyric Acid and Modifications on Its Metabolic Pathways in Black Rice Grains by Germination under Cold Stressncbi.nlm.nih.gov
138. Enrichment of GABA content in brown rice through heating and humidifying treatment: Quantification via TLC-ImageJ method - ScienceDirectsciencedirect.com
139. Self-enhancement of GABA in rice bran using various stress treatments - ScienceDirectsciencedirect.com
140. (PDF) Effect of soaking and gaseous treatment on GABA content in germinated brown riceresearchgate.net
141. Effects of magnetic field pretreatment and chloride salt stress on physio-biochemical changes and γ-aminobutyric acid accumulation in germinated brown ricemaxapress.com
142. United States Pharmacopeia (USP) Safety Review of Gamma-Aminobutyric Acid (GABA) - PMCpmc.ncbi.nlm.nih.gov
143. Repeated oral administration of gamma-aminobutyric acid (GABA) does not cause reproductive or developmental toxicity in rats - PMCpmc.ncbi.nlm.nih.gov
144. GABA gains traction in functional formulationsvitafoodsinsights.com
145. Global Comparison of GABA Laws: Worldwide Regulationsmagnesiumsleep.uk
146. Exploring the Therapeutic Potential of Gamma-Aminobutyric Acid in Stress and Depressive Disorders through the Gut–Brain Axisncbi.nlm.nih.gov
147. Frontiersfrontiersin.org
148. Gamma-aminobutyric acid - Scholarpediascholarpedia.org
149. Frontiersfrontiersin.org
150. JBC: The discovery of GABA in the brainasbmb.org
151. User:Eugene Roberts - Scholarpediascholarpedia.org
152. Endogenous Positive Allosteric Modulation of GABAA Receptors by Diazepam binding inhibitor: Neuroncell.com
153. Benzodiazepine Receptor - an overviewsciencedirect.com
154. Structure of Ionotropic Glutamate Receptorslink.springer.com
155. A half century of γ-aminobutyric acid - Trevor G Smart, F Anne Stephenson, 2019journals.sagepub.com
156. The Molecular Biology of GABAA Receptors and Its Applicationslink.springer.com
157. Evolution of GABAA Receptor–Like Genesacademic.oup.com
158. The discovery of GABA in the brain - Journal of Biological Chemistryjbc.org
159. Frontiersfrontiersin.org
160. Tonic GABAA receptor-mediated signalling in temporal lobe epilepsy - ScienceDirectsciencedirect.com
161. GABAA receptor subtypes: dissecting their pharmacological functions - ScienceDirectsciencedirect.com
162. Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primatespnas.org
163. Drug interactions at GABA A receptorssciencedirect.com
164. GABAergic signaling beyond synapses: an emerging target for cancer therapy - ScienceDirectsciencedirect.com
165. Distinctive GABA A receptor subunit expression modulates cell specific EMT and functional responses in glioblastoma breast and ovarian cancernature.com
166. Extrasynaptic GABAA Receptors: Form, Pharmacology, and Functionjneurosci.org
167. Pathophysiological power of improper tonic GABAA conductances in mature and immature modelsncbi.nlm.nih.gov
168. Re-Evaluation of the Ultrastructural Localization of Tonic GABA-A Receptorsncbi.nlm.nih.gov
169. Tonic GABAA Receptor-Mediated Signaling in Epilepsy - Jasper's Basic Mechanisms of the Epilepsies - NCBI Bookshelfncbi.nlm.nih.gov
170. Differential drug responses on native GABA(A) receptors revealing heterogeneity in extrasynaptic populations in cultured hippocampal neurons - PubMedpubmed.ncbi.nlm.nih.gov
171. Frontiersfrontiersin.org
172. GABAB receptor regulates proliferation in the high-grade chondrosarcoma cell line OUMS-27 via apoptotic pathwaysbmccancer.biomedcentral.com
173. Gamma-Aminobutyric Acid Induces Tumor Cells Apoptosis via GABABR1·β-Arrestins·JNKs Signaling Modulelink.springer.com